Advanced lung cancer inflammation index (ALI) association with increased risk of immune related adverse events (irAE) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy

V. Bhat; M. Millward; E. S. Gray; A. Abed

doi:10.1016/j.annonc.2022.10.378

Advanced lung cancer inflammation index (ALI) association with increased risk of immune related adverse events (irAE) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy

V. Bhat, M. Millward, E. S. Gray, A. Abed

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S1575-S1575
Number of pages	1
Journal	Annals of Oncology
Volume	33
DOIs	https://doi.org/10.1016/j.annonc.2022.10.378
Publication status	Published - Nov 2022
Event	ESMO Asia Congress - Singapore, Singapore Duration: 2 Dec 2022 → 4 Dec 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2022.10.378

Cite this

@article{abfdcbcae4bb4724ac81e1b5a993e644,

title = "Advanced lung cancer inflammation index (ALI) association with increased risk of immune related adverse events (irAE) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy",

author = "V. Bhat and M. Millward and Gray, {E. S.} and A. Abed",

year = "2022",

month = nov,

doi = "10.1016/j.annonc.2022.10.378",

language = "English",

volume = "33",

pages = "S1575--S1575",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

note = "ESMO Asia Congress ; Conference date: 02-12-2022 Through 04-12-2022",

}

Advanced lung cancer inflammation index (ALI) association with increased risk of immune related adverse events (irAE) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy. / Bhat, V.; Millward, M.; Gray, E. S. et al.
In: Annals of Oncology, Vol. 33, 11.2022, p. S1575-S1575.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - Advanced lung cancer inflammation index (ALI) association with increased risk of immune related adverse events (irAE) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy

AU - Bhat, V.

AU - Millward, M.

AU - Gray, E. S.

AU - Abed, A.

PY - 2022/11

Y1 - 2022/11

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000897943700345

U2 - 10.1016/j.annonc.2022.10.378

DO - 10.1016/j.annonc.2022.10.378

M3 - Abstract/Meeting Abstract

SN - 0923-7534

VL - 33

SP - S1575-S1575

JO - Annals of Oncology

JF - Annals of Oncology

T2 - ESMO Asia Congress

Y2 - 2 December 2022 through 4 December 2022

ER -

Advanced lung cancer inflammation index (ALI) association with increased risk of immune related adverse events (irAE) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy

UN SDGs

Access to Document

Other files and links

Advanced lung cancer inflammation index (ALI) association with increased risk of immune-related adverse events (irAEs) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy

Cite this